摘要
为探讨肠炎宁胶囊联合美沙拉嗪口服治疗溃疡性结肠炎(UC)的效果及安全性,将我院2016年收治的72例UC患者随机分为对照组和观察组,各36例,对照组n服美沙拉嗪治疗,观察组在对照组基础上口服肠炎宁胶囊。对比2组患者总体疗效,治疗前后血清白介素1(IL-1)、IL-8、纤维蛋白原(Fib)、D-二聚体水平,以及不良反应。结果显示,观察组总有效率(97.22%)明显高于对照组(80.56%),差异有统计学意义,P<0.05。观察组治疗后IL-1、IL-8、Fib、D-二聚体水平均较治疗前明显降低,P<0.05;其中观察组各指标降低更明显,观察组治疗后明显低于对照组,P<0.05。观察组不良反应发生率为5.56%,对照组为2.78%,差异无统计学意义,P>0.05。结果表明,肠炎宁胶囊联合美沙拉嗪口服治疗UC,可减轻炎症反应,改善凝血功能,提高治疗疗效,且不良反应少,是一种较理想的治疗方案。
This study was to explore the effect and safety of oral administration of Changyanning capsule plus mesalazine for treating ulcerative eolitis（UC）, randomly divided 72 UC patients admitted in author＇s hospital in 2016 yr. into control group and observation group,36 cases for each,which the former orally administered mesalazine, based on this the latter was added oral Changyanning capsule;then compared whole effect, the levels of IL-1, IL-8, Fib and D dimer before and after treatment, as well as adverse reaction. As results,in observation group total effective rate was signifiantly higher than that in control group（ 97.22 % vs 80.56%） ,there was statistical difference （ P 〈0.05） ; the levels of IL-1, IL-8, Fib and D-dimer after treatment in observation group were all significantly decline than before treatment（ P 〈0.05）,and lower decline of all indexes in observation group,even significantly lower than that in control group（ P 〈0.05）, the incidence of adverse reaction had no statistical difference（5.56% vs 2.78%, P 〉0.05）.Results show that oral administration of Changyanning capsule plus mesalazine for treating UC can reduce inflammatory response, improve coagulation function, uplift effect, and have less adverse reaction, thus is more ideal therapy.
作者
姚志毅
YAO Zhi-yi(Dingxi City＇s Hospital of TCM ,Dingxi ,Gansu 74300)
出处
《中国肛肠病杂志》
2018年第2期39-41,共3页
Chinese Journal of Coloproctology
关键词
溃疡性结肠炎
肠炎宁胶囊
美沙拉嗪
炎性因子
凝血指标
效果
Ulcerative colitis
Changyanning capsule
Mesalazine
Inflammatory factor
Coagulation indexes
Efficacy
